TEVIMBRA
GrowthmAbBLAINTRAVENOUSINJECTABLE
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEVIMBRA (tislelizumab-jsgr) is a monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing immune checkpoint inhibition to enhance anti-tumor T-cell responses. It is approved for metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy. The drug restores immune surveillance by preventing tumor-mediated T-cell exhaustion.
Growth
Early-stage growth product with emerging commercial opportunity; commercial team is small but expanding as market penetration develops.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TEVIMBRA offers entry into a high-value oncology immunotherapy segment with a newly approved product in growth phase. Roles are currently concentrated in commercial leadership, signaling emphasis on market launch, reimbursement strategy, and sales infrastructure build-out.
Director
Commercial
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.